Apple Watch Series 4 review: beautiful screen, great battery life, and health-tracking features, but Siri is unreliable, and there is no always-on screen option
enough to collect data about arrhythmia but not to diagnose a heart attack. http://www.nytimes.com/... Daniel Rubino / @daniel_rubino : Use Apple Watch for 5 minutes and I'm instantly reminded of why I don't like wearing it. Still big, too heavy, too much stuff I don't use like apps. Not enough stuff I want to use like weight workouts, or sleep data. Will be selling off soon. Just something I can't get into. Nicholas Bagley / @nicholas_bagley : One thing we know: annual physicals don't improve health. They can lead to a cascade of testing and overdiagnosis. And they're expensive. http://jamanetwork.com/... So what the hell is going to happen when we've all got mini-EKGs on our wrists? http://www.nytimes.com/... Pui-Wing Tam / @puiwingtam : In the name of journalism and a review of the new Apple Watch, @bxchen got an EKG and fell from a 17-foot wall to trigger the device's health functionshttps://t.co/QicshvjLP1 Dan Graziano / @dangraziano : Great battery life? In what world is 18 hours great battery life? To make matters worse there is no sleep tracking. The reality distortion field is alive and well today. http://twitter.com/...
Context & Ripple Effects
This review lands at the pivot point of Apple's wearable line: since the 2015 original, The Verge's verdicts have tracked a shift from app-platform ambitions toward health sensing, and the Series 4 is where that shift becomes the headline feature — EKG and arrhythmia-grade heart tracking alongside the usual screen-and-battery assessment.
The two gaps the review names both got addressed on Apple's own schedule: the always-on display arrived a year later in the Series 5, while Siri's unreliability has persisted across the line — commentators trace its poor performance back roughly fifteen years.
First-order effects
- Buyers deciding between the Series 4 and cheaper or older Apple Watches are choosing on exactly the axes this review isolates: health sensors and display behavior, not apps — the same trade-off Apple later formalized by shipping the Watch SE with the Series 4's performance but no always-on display and no ECG.
- The review draws a hard line on the health claims: the watch collects arrhythmia-suggestive data but cannot diagnose a heart attack, which caps what early adopters can act on without a clinician.
Second-order effects
- Feature tiering becomes Apple's pricing lever — the always-on display and ECG split the lineup into premium and value tiers rather than aging out uniformly, forcing buyers to pay up specifically for health and display features.
- Clinicians begin using the watch for diagnostic and disease-management purposes it was never FDA-approved for, pulling regulators into territory the product marketing stops short of claiming.
Third-order effects
- If the pattern holds, the smartwatch consolidates around continuous health observation while the diagnosis step stays with the medical system — an observation–synthesis boundary that regulators and insurers will eventually have to price.
- Assistant quality emerges as the durable weak point across otherwise strong hardware generations, making voice reliability a competitive axis Apple keeps losing on regardless of sensor wins.
The trend: Smartwatch competition is shifting from apps and screens to graded health sensing, with each generation adding clinical-adjacent features faster than regulation and assistants keep pace.